April 2023 in “Journal of Pakistan Medical Association” Baricitinib is effective in promoting hair growth in severe alopecia areata.
Thymosin β4 helps with healing, inflammation, and organ protection.
March 2025 in “International Journal of Dermatology” Baricitinib may help people with long-term alopecia areata.
1 citations
,
February 2013 in “Steroids” Bone mineral and minocycline boost bone cell growth, aiding healing.
Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.
July 2025 in “Pakistan Journal of Intensive Care Medicine” Clobetasol propionate 0.05% ointment is more effective than tacrolimus 0.1% ointment for treating alopecia areata.
19 citations
,
April 2014 in “Expert opinion on emerging drugs” New treatments for a type of skin cancer show promise but have side effects and may work better with other therapies.
January 2024 in “Journal of Applied Health Sciences and Medicine” Nephrolepis biserrata may improve fertility and reduce prostate issues in males.
April 2026 in “Meditsinskiy sovet = Medical Council” Tofacitinib and baricitinib are similarly effective and safe for alopecia areata, but baricitinib works faster.
12 citations
,
September 2012 in “Pediatric Dermatology” The boy's skin condition improved significantly with a specific ointment after other treatments showed only mild results.
Activin B helps start and grow hair follicles in mice.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” Baricitinib is effective and safe for treating severe alopecia areata.
2 citations
,
December 2022 in “PNAS nexus” SCD-153 shows promise as an effective topical treatment for alopecia areata.
3 citations
,
October 2018 in “Archives of Dermatological Research” Applying InlB321/15 to wounds sped up healing in mice.
13 citations
,
November 2021 in “Pediatric Dermatology” Tofacitinib taken by mouth helps treat hair loss in children.
October 2025 in “Archives of Dermatological Research” Topical metformin gel is as effective and safe as steroids for treating alopecia areata.
7 citations
,
August 2024 in “Clinical and Experimental Dermatology” Upadacitinib is effective and safe for treating severe alopecia areata in teens.
January 2024 in “International journal of molecular sciences” A brain-made hormone can protect against memory-related brain damage caused by harmful proteins.
36 citations
,
July 2017 in “Journal of controlled release” A new method allows for controlled, long-lasting delivery of retinoic acid through the skin with fewer side effects.
September 2023 in “International Journal of Applied Pharmaceutics” The formulated gel is a promising treatment for alopecia areata.
February 2026 in “Frontiers in Immunology” Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
227 citations
,
April 2023 in “The Lancet” Ritlecitinib effectively treats alopecia areata and is well-tolerated.
72 citations
,
October 1988 in “Archives of Disease in Childhood” Biotin treatment improves symptoms of biotinidase deficiency, but some neurological damage may be permanent.
9 citations
,
November 1980 in “Geburtshilfe und Frauenheilkunde” Fenoterol treatment causes increased hair growth due to higher metabolism in hair follicles, not hormones.
Bicalutamide does not significantly affect liver enzymes and is a safe anti-androgen option for transfeminine individuals.
68 citations
,
February 2011 in “European Journal of Pharmaceutics and Biopharmaceutics” Keratin films from human hair can potentially replace human nail plates for drug testing.
1 citations
,
February 2022 in “Clinical and Experimental Health Sciences” Dexpanthenol may help treat epilepsy and depression.
Eye drops with β-blockers may cause hair loss.
October 2023 in “Dermatology practical & conceptual” Pulse corticosteroids help regrow hair in alopecia areata but have side effects, especially betamethasone.
3 citations
,
July 2016 in “Tropical Journal of Pharmaceutical Research” Splitting non-scored tablets can lead to uneven drug distribution, posing risks.